Skip to main content
MPLT
NASDAQ Life Sciences

Former Affiliate Novo Holdings Plans $24M Share Sale After Positive Trial Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$14.5
Mkt Cap
$597.933M
52W Low
$9.1
52W High
$40.43
52W Position info
59% above low
Off High info
64% below high
Rel. Volume info
4.5× avg
Market data snapshot near publication time

MPLT sits 59% above its 52-week low of $9.1 on elevated volume (4.5× avg).

Summary

Former affiliate Novo Holdings A/S filed a Form 144 to sell 1.6 million shares (~$24M) of MapLight Therapeutics, representing about 3.5% of outstanding shares, shortly after positive Phase 2 trial results.


Key Events · Ownership and Investor Activity · MPLT

  • Novo Holdings Plans $24M Share Sale

    Former affiliate Novo Holdings A/S filed a Form 144 to sell 1,600,000 shares of MapLight Therapeutics, with an approximate market value of $24,032,000 based on the filing date price.

  • Sale Represents ~3.5% of Outstanding Shares

    The 1.6 million shares to be sold equal about 3.5% of the 45,345,676 shares outstanding, a significant block that could pressure the stock.

  • Timing Follows Positive Phase 2 Data

    The filing comes three days after MapLight announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia, a catalyst that boosted the stock price and may have prompted the sale.

  • No Prior Sales by Novo in Past 3 Months

    The Form 144 indicates no sales by Novo Holdings in the prior three months, making this the first reported disposition by this holder.


Analysis · MPLT · Life Sciences

Just three days after MapLight Therapeutics announced positive Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia—news that lifted the stock—former affiliate Novo Holdings A/S filed to sell 1.6 million shares worth approximately $24 million. The sale represents about 3.5% of outstanding shares and marks the first reported disposition by this holder. Although Novo is no longer an insider, the size and timing following a major catalyst could signal a strategic exit or portfolio rebalancing by a large early investor.

At the time of this filing, MPLT was trading at $14.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.9M. The 52-week trading range was $9.10 to $40.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MPLT - Latest Insights

MPLT
Jul 30, 2026, 6:39 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $13.78
Real-time Price: $14.50 info
Change: +$0.7213 (+5%) info
Market Cap: $597.933M info
MPLT
Jul 27, 2026, 8:27 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.42
Real-time Price: $14.50 info
Change: +$0.0801 (+0.56%) info
Market Cap: $597.933M info
MPLT
Jul 27, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.62
Real-time Price: $14.50 info
Change: -$2.12 (-13%) info
Market Cap: $597.933M info
MPLT
Jul 17, 2026, 9:46 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $37.87
Real-time Price: $14.50 info
Change: -$23.37 (-62%) info
Market Cap: $597.933M info
MPLT
Jun 22, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.92
Real-time Price: $14.50 info
Change: -$11.42 (-44%) info
Market Cap: $597.933M info